For the first time, we demonstrated conclusively that TALE-TFs targeting the SMN2 promoter can facilitate site-specific transcriptional modulation in SMA pathology and can robustly increase endogenous SMN2 mRNA. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.